Clinical trials
Injection clinical trials
Below are recruiting injection clinical trials, each written for real people, not researchers. We’re tracking 2,089 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06533358RecruitingPhase 2
Testing MT1002 for heart attack patients getting a stent
This study tests an investigational medicine called MT1002 in people who have had a heart attack and are about to get a stent (PCI). The goal is to see if MT1002 helps prevent further heart problems.
Beijing, Beijing MunicipalityAges 18–85 - NCT06534021RecruitingPhase 1
Study of IASO-782 for autoimmune blood disorders
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Wuhan, HubeiAges 18–65 - NCT06535789RecruitingPhase 2/Phase 3
Inhaled insulin vs injections for gestational diabetes
This trial compares an inhaled insulin (Afrezza) to insulin injections for managing blood sugar after meals in women with gestational diabetes. The goal is to see if the inhaled option works as well and is easier to use.
Santa Barbara, CaliforniaAges 18–40 - NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+ - NCT06539624Recruiting
Testing a new gene therapy for Fabry disease
This trial is testing a new treatment called EXG110 for people with Fabry disease. It's designed to see if it's safe and if it can help. You may be able to join if you have a confirmed diagnosis and at least one symptom of Fabry disease.
Shanghai, Shanghai MunicipalityAges 7 years+ - NCT06541028Recruiting
Quick-start HIV treatment study for people who inject drugs
This study tests a rapid-start antiretroviral therapy (ART) approach for people who inject drugs and have HIV. The goal is to see if starting HIV medicine quickly helps reduce stigma and improve health outcomes.
KajangAges 18 years+ - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06555809Recruiting
Artesunate study for infants with severe malaria
This trial studies how artesunate works in infants under 2 years old being treated for severe malaria. It aims to learn more about the medicine to help improve treatment for babies.
ParisAges 1 minute–1.9 years - NCT06558227RecruitingPhase 2
ZG005 with bevacizumab vs sintilimab with bevacizumab for advanced liver cancer
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Chengdu, SichuanAges 18–75 - NCT06564805Recruiting
Steroid vs. yeast extract injection for patchy hair loss
This trial compares two injections—triamcinolone (a steroid) and candida albicans antigen (a yeast extract)—to see which works better for alopecia areata (patchy hair loss). You might benefit if you have mild to moderate hair loss and haven't used other treatments recently.
Monterrey, Nuevo LeónAges 6 years+ - NCT06568094RecruitingPhase 1/Phase 2
Study of HRS-5041 with other drugs for advanced prostate cancer
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
Harbin, HeilongjiangAges 18–80 - NCT06569524RecruitingPhase 2
A new drug for NASH with liver scarring
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Lu'an, AnhuiAges 18–75 - NCT06569459RecruitingPhase 2
Trilaciclib with chemoradiation and immunotherapy for esophageal cancer
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
Nanjing, JiangsuAges 18 years+ - NCT06569953RecruitingPhase 4
Numbing Medicine for Pain After Lung Surgery
This study tests whether a long-lasting numbing medicine (liposomal bupivacaine) injected near the spine can better control pain after lung surgery. It compares this to a standard numbing medicine, and aims to help patients recover with less pain after surgery.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06570291RecruitingPhase 3
Stem cell injection for knee osteoarthritis
This trial tests a new treatment using donor stem cells injected into the knee for people with moderate knee osteoarthritis. It aims to see if these cells can reduce pain and improve function.
Shanghai, ChinaAges 40–75 - NCT06572085RecruitingPhase 4
Butylphthalide for brain protection after cardiac arrest
This trial tests a medicine called butylphthalide (NBP) to see if it helps protect the brain after a cardiac arrest. It is for adults who remained unconscious after their heart was restarted.
Beijing, Beijing MunicipalityAges 18–80 - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06584162RecruitingPhase 4
Can vedolizumab be given less often for Crohn's or colitis?
This research study tests whether taking vedolizumab injections less often (every 4 weeks instead of every 2 weeks) can still keep your Crohn's or colitis in remission. If you are already well-controlled on standard vedolizumab, this study may help you and others by reducing the number of injections needed.
AmsterdamAges 18 years+ - NCT06591793RecruitingPhase 1/Phase 2
Gene therapy for Usher syndrome type 1B vision loss
This trial tests an experimental gene therapy given as an injection under the retina. It aims to slow or stop vision loss in people with Usher syndrome type 1B, a rare genetic condition that causes both hearing and vision problems.
NaplesAges 18–50 - NCT06595355RecruitingPhase 2/Phase 3
Study of eye injections with or without curcumin for diabetic eye swelling
This trial tests whether adding oral curcumin (a natural supplement) to standard eye injections (bevacizumab) improves treatment for diabetic macular edema, a swelling in the back of the eye that can affect vision.
Isfahan, Isfahan University of Medical SciencesAges 40 years+ - NCT06596291RecruitingPhase 1/Phase 2
Gene therapy trial for bladder control after spinal cord injury
This trial tests a new gene therapy called EG110A for people with overactive bladders due to spinal cord injury. It aims to reduce urinary incontinence and may offer an option if other treatments haven't worked well.
Downey, CaliforniaAges 18–75 - NCT06597916RecruitingPhase 2
RSV vaccine study for people with weakened immune systems
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
ViennaAges 18 years+ - NCT06598787RecruitingPhase 2
Study of a new drug for recurrent glioblastoma
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Injection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for injection?
- Yes. Clin2 currently lists 2,089 recruiting injection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a injection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a injection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.